Tracey O'Connor, MD

Cancer Focus:
Breast Cancer

Dr. Tracey O’Connor in an Associate Member in the Department of Breast Oncology at Moffitt Cancer Center. Dr. O’Connor received her MD degree from The State University of New York (SUNY) at Buffalo, Jacobs School of Medicine and Biological Sciences. She completed an Internal Medicine Residency at Strong Memorial Hospital, University of Rochester Medical Center, followed by a Medical Oncology Fellowship at Roswell Park Comprehensive Cancer Center, Buffalo, New York. Dr. O’Connor’s most recent appointment was as Associate Professor of Oncology at Roswell Park Comprehensive Cancer Center and a Clinical Associate Professor at The State University of New York at Buffalo. Dr. O’Connor’s clinical interests focus on the care of breast cancer patients. Her research interests are centered around predicting and understanding the toxicity of therapies and developing strategies to mitigate side effects, particularly in improving the tolerability of treatment for older breast cancer patients.

Clinical Trial 23393
A Phase 2, Open-Label Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer
Condition: Breast
Intervention: PCS6422 (); Xeloda (capecitabine); capecitabine ()
Status: OPEN (SUSPENDED)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Parker NH, de Cerqueira Santos A, Mintrone R, Turner K, Sutton SK, O'Connor T, Huang J, Lael M, Cruff S, Grassia K, De Vera MT, Bean M, Carmella R, Vadaparampil ST, Vidrine JI. Feasibility, Acceptability, and Outcomes of Project Rally: Pilot Study of a YMCA-Based Pickleball Program for Cancer Survivors. Healthcare (Basel). 2025 Jan.13(3). Pubmedid: 39942445. Pmcid: PMC11817839.
• Basta A, Lien K, Sun W, Whiting J, Armitage M, Soyano AE, Armaghani A, Loftus L, O Apos Connor T, Dvir K, Han HS, Soliman H, Czerniecki BJ, Costa RLB. A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer. Oncology-Basel. 2025 Aug.1-10. Pubmedid: 40759100.
• Sarfraz H, Zahra FT, Joshi U, O'Connor T. Addressing the Needs of Breast Cancer Survivors. Curr Oncol Rep. 2025 Aug.27(8):986-1001. Pubmedid: 40512438. Pmcid: PMC12423176.
• Ji J, Bae M, Sun CL, Wildes TM, Freedman RA, Magnuson A, O'Connor T, Moy B, Klepin HD, Chapman AE, Tew WP, Dotan E, Fenton MA, Kim H, Katheria V, Gross CP, Cohen HJ, Muss HB, Sedrak MS. Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial. Cancer. 2024 Mar.130(6):936-946. Pubmedid: 37962093. Pmcid: PMC10922500.
• Sedrak MS, Lee MK, Ji J, Satele DV, Freedman RA, Poorvu PD, O'Connor T, Williams GR, Hopkins JO, Muss HB, Cohen HJ, Partridge AH, Carey LA, Chow SL, Subbiah N, Le-Rademacher J, Jatoi A. Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601). Geriatr Oncol. 2024 Jul.15(6):101813. Pubmedid: 38852379. Pmcid: PMC11259237.
• Sedrak MS, Sun CL, Bae M, Freedman RA, Magnuson A, O'Connor T, Moy B, Wildes TM, Klepin HD, Chapman AE, Tew WP, Dotan E, Fenton MA, Kim H, Katheria V, Muss HB, Cohen HJ, Gross CP, Ji J. Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study. J Cancer Surviv. 2024 Aug.18(4):1131-1143. Pubmedid: 38678525. Pmcid: PMC11324395.
• Sedrak MS, Sun CL, Ji J, Cohen HJ, Gross CP, Tew WP, Klepin HD, Wildes TM, Dotan E, Freedman RA, O'Connor T, Chow S, Fenton MA, Moy B, Chapman AE, Dale W, Katheria V, Kuderer NM, Lyman GH, Magnuson A, Muss HB. Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. J Clin Oncol. 2023 Jan.41(2):316-326. Pubmedid: 36455189. Pmcid: PMC9839299.
• Ademuyiwa FO, Northfelt DW, O'Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury ML, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Iglesia MD, Ma CX. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ Breast Cancer. 2023 Jan.9(1):1. Pubmedid: 36609389. Pmcid: PMC9822956.
• Martin MG, Chidebe RCW, Nwaneri MO, Miller E, Okoye I, Esiaka DK, Olasinde TA, Durosinmi-Etti FA, Igbinoba F, Adegboyega BC, Adenjii A, Aruah CS, Orjiakor TC, Abubakar BM, Atuwo D, O'Connor T. Impact of 10-Day Fulbright Specialist Program and Project Pink Blue Education Sessions on Medical Oncology Knowledge Among Physicians Who Treat Cancer in Nigeria. J Cancer Educ. 2023 Feb.38(1):378-382. Pubmedid: 35838882.
• Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines® Insights: Survivorship, Version 1.2022. J Natl Compr Canc Ne. 2022 Oct.20(10):1080-1090. Pubmedid: 36240847.
• Alaklabi S, Roy AM, Attwood K, George A, O'Connor T, Early A, Levine EG, Gandhi S. Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. Front Oncol. 2022 Oct.12:1012391. Pubmedid: 36338738. Pmcid: PMC9631302.
• McCann SE, Rodriguez EM, Erwin D, Yao S, Tritchler D, Hullar MAJ, O'Connor T, Lampe JW. Recruitment and Retention of Healthy, Postmenopausal Women of African and European Ancestry: Results from a Dietary Intervention with Repeated Biospecimen Collections. Curr Dev Nutr. 2022 Mar.6(3):nzac012. Pubmedid: 35261959. Pmcid: PMC8894291.
• Cross T, George A, Attwood K, Zhang Y, O'Connor TL, Barone N, Hulme K, Ambrosone CB, Yao S, Hong CC. Associations between Serum 25-Hydroxyvitamin D Levels and Health-Related Quality-of-Life Measures in Patients with Breast Cancer: A Longitudinal Study. Cancer Epidemiol Biomarkers Prev. 2022 Dec.31(12):2126-2135. Pubmedid: 36126952. Pmcid: PMC9729381.
• Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O'Connor T, Levine E, Witkiewicz AK. Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center. Oncologist. 2022 Aug.27(8):646-654. Pubmedid: 35666660. Pmcid: PMC9355808.
• Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O'Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S. Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study. Breast Cancer Res Treat. 2022 Apr.192(2):411-421. Pubmedid: 35000093. Pmcid: PMC9997691.
• Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, Gross C, Gupta S, Hollis G, Hubbard J, Jagsi R, Keating NL, Kessler E, Koll T, Korc-Grodzicki B, McKoy JM, Misra S, Moon D, O'Connor T, Owusu C, Rosko A, Russell M, Sedrak M, Siddiqui F, Stella A, Stirewalt DL, Subbiah IM, Tew WP, Williams GR, Hollinger L, George GV, Sundar H. NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Ne. 2021 Sep.19(9):1006-1019. Pubmedid: 34551388.
• Lang JK, Karthikeyan B, Quiñones-Lombraña A, Blair RH, Early AP, Levine EG, Sharma UC, Blanco JG, O'Connor T. CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin. Cardiooncology. 2021 May.7(1):17. Pubmedid: 33975650. Pmcid: PMC8111996.
• McCann SE, Hullar MAJ, Tritchler DL, Cortes-Gomez E, Yao S, Davis W, O'Connor T, Erwin D, Thompson LU, Yan L, Lampe JW. Enterolignan Production in a Flaxseed Intervention Study in Postmenopausal US Women of African Ancestry and European Ancestry. Nutrients. 2021 Mar.13(3). Pubmedid: 33809130. Pmcid: PMC8001909.
• Tevaarwerk A, Denlinger CS, Sanft T, Ansbaugh SM, Armenian S, Baker KS, Broderick G, Day A, Demark-Wahnefried W, Dickinson K, Friedman DL, Ganz P, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Zee P, McMillian NR, Freedman-Cass DA. Survivorship, Version 1.2021. J Natl Compr Canc Ne. 2021 Jun.19(6):676-685. Pubmedid: 34214969. Pmcid: PMC8375577.
• Magnuson A, Sedrak MS, Gross CP, Tew WP, Klepin HD, Wildes TM, Muss HB, Dotan E, Freedman RA, O'Connor T, Dale W, Cohen HJ, Katheria V, Arsenyan A, Levi A, Kim H, Mohile S, Hurria A, Sun CL. Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. J Clin Oncol. 2021 Feb.39(6):608-618. Pubmedid: 33444080. Pmcid: PMC8189621.
• Dhakal A, Antony Thomas R, Levine EG, Brufsky A, Takabe K, Hanna MG, Attwood K, Miller A, Khoury T, Early AP, Soniwala S, O'Connor T, Opyrchal M. Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. Breast Cancer (Auckl). 2020 Jul.14. Pubmedid: 32753876. Pmcid: PMC7378710.
• Denlinger CS, Sanft T, Moslehi JJ, Overholser L, Armenian S, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, O'Connor T, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines Insights: Survivorship, Version 2.2020. J Natl Compr Canc Ne. 2020 Aug.18(8):1016-1023. Pubmedid: 32755975. Pmcid: PMC7785060.
• Sanft T, Denlinger CS, Armenian S, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Mooney K, Moore HCF, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines Insights: Survivorship, Version 2.2019. J Natl Compr Canc Ne. 2019 Jul.17(7):784-794. Pubmedid: 31319383. Pmcid: PMC7094216.
• Hepner A, Negrini D, Hase EA, Exman P, Testa L, Trinconi AF, Filassi JR, Francisco RPV, Zugaib M, O'Connor TL, Martin MG. Cancer During Pregnancy: The Oncologist Overview. World J Oncol. 2019 Feb.10(1):28-34. Pubmedid: 30834049. Pmcid: PMC6396773.
• Peoples AR, Culakova E, Heckler CE, Shayne M, O'Connor TL, Kirshner JJ, Bushunow PW, Morrow GR, Roscoe JA. Positive effects of acupressure bands combined with relaxation music/instructions on patients most at risk for chemotherapy-induced nausea. Support Care Cancer. 2019 Dec.27(12):4597-4605. Pubmedid: 30929028. Pmcid: PMC6768770.
• Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Oct.16(10):1216-1247. Pubmedid: 30323092. Pmcid: PMC6438378.
• Dhakal A, Matthews CM, Levine EG, Salerno KE, Zhang F, Takabe K, Early AP, Edge SB, O'Connor T, Khoury T, Young JS, Opyrchal M. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment. Clin Breast Cancer. 2018 Dec.18(6):e1401-e1405. Pubmedid: 29778787.
• Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Sep.15(9):1140-1163. Pubmedid: 28874599. Pmcid: PMC5865602.
• Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. Jama. 2017 Jan.317(1):48-58. Pubmedid: 28030702. Pmcid: PMC5321662.
• VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A. NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. J Natl Compr Canc Ne. 2016 Nov.14(11):1357-1370. Pubmedid: 27799507.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Sanft T, Silverman P, Smith S, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines Insights: Survivorship, Version 1.2016. J Natl Compr Canc Ne. 2016 Jun.14(6):715-724. Pubmedid: 27283164. Pmcid: PMC5865597.
• Mix M, Elmarzouky R, O'Connor T, Plunkett R, Prasad D. Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy. J Neurosurg. 2016 Dec.125(Suppl 1):26-30. Pubmedid: 27903186.
• O'Connor TL, Ngamphaiboon N, Groman A, Luczkiewicz DL, Kuszczak SM, Grant PC, Kerr CW. Hospice utilization and end-of-life care in metastatic breast cancer patients at a comprehensive cancer center. J Palliat Med. 2015 Jan.18(1):50-55. Pubmedid: 25353618.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: healthy lifestyles, version 2.2014. J Natl Compr Canc Ne. 2014 Sep.12(9):1222-1237. Pubmedid: 25190692. Pmcid: PMC4465248.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2014 Oct.12(10):1396-1406. Pubmedid: 25313179. Pmcid: PMC4465236.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: screening for cancer and treatment effects, version 2.2014. J Natl Compr Canc Ne. 2014 Nov.12(11):1526-1531. Pubmedid: 25361799. Pmcid: PMC4771020.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: sleep disorders, version 1.2014. J Natl Compr Canc Ne. 2014 May.12(5):630-642. Pubmedid: 24812132. Pmcid: PMC4771023.
• Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: sexual dysfunction (male), version 1.2013. J Natl Compr Canc Ne. 2014 Mar.12(3):356-363. Pubmedid: 24616541. Pmcid: PMC4465261.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: fatigue, version 1.2014. J Natl Compr Canc Ne. 2014 Jun.12(6):876-887. Pubmedid: 24925198. Pmcid: PMC4465265.
• DeNysschen CA, Burton H, Ademuyiwa F, Levine E, Tetewsky S, O'Connor T. Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study. Eur J Cancer Care (Engl). 2014 Jul.23(4):493-501. Pubmedid: 24289215.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: cognitive function, version 1.2014. J Natl Compr Canc Ne. 2014 Jul.12(7):976-986. Pubmedid: 24994918. Pmcid: PMC4465252.
• Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, Dotan E, Edil BH, Extermann M, Ganti AK, Holmes HM, Jagsi R, Karlekar MB, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Weir AB, Bergman MA, Sundar H. Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . J Natl Compr Canc Ne. 2014 Jan.12(1):82-126. Pubmedid: 24453295.
• Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: introduction and definition. Clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2014 Jan.12(1):34-45. Pubmedid: 24453291. Pmcid: PMC4465253.
• Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: sexual dysfunction (female), version 1.2013. J Natl Compr Canc Ne. 2014 Feb.12(2):184-192. Pubmedid: 24586080. Pmcid: PMC4465262.
• Jitawatanarat P, O'Connor TL, Kossoff EB, Levine EG, Chittawatanarat K, Ngamphaiboon N. Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer. J Breast Cancer. 2014 Dec.17(4):356-362. Pubmedid: 25548584. Pmcid: PMC4278055.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: immunizations and prevention of infections, version 2.2014. J Natl Compr Canc Ne. 2014 Aug.12(8):1098-1111. Pubmedid: 25099442. Pmcid: PMC4465238.
• Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D. Survivorship: pain version 1.2014. J Natl Compr Canc Ne. 2014 Apr.12(4):488-500. Pubmedid: 24717568. Pmcid: PMC4465256.
• Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Karpf AR, James SA, Ambrosone CB, O'Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One. 2013 Mar.7(6):e38783. Pubmedid: 22761704. Pmcid: PMC3386262.
• O'Connor T, Shinde A, Doan C, Katheria V, Hurria A. Managing breast cancer in the older patient. Clin Adv Hematol Oncol. 2013 Jun.11(6):341-347. Pubmedid: 24472802. Pmcid: PMC3906632.
• Ngamphaiboon N, O'Connor TL, Advani PP, Levine EG, Kossoff EB. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis. Med Oncol. 2012 Sep.29(3):1495-1501. Pubmedid: 21818673.
• Bush E, Lamonica D, O'Connor T. Sarcoidosis mimicking metastatic breast cancer. Breast J. 2012 Feb.17(5):533-535. Pubmedid: 21827559.
• Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB, Wildes T. Senior adult oncology. J Natl Compr Canc Ne. 2012 Feb.10(2):162-209. Pubmedid: 22308515. Pmcid: PMC3656650.
• Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. 2011 Sep.117(18):4132-4140. Pubmedid: 21387276.
• Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, Nesline MK, Davis W, Hong CC, McCann SE, Hwang H, Kulkarni S, Edge SB, O'Connor TL, Ambrosone CB. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One. 2011 Feb.6(2):e17251. Pubmedid: 21386992. Pmcid: PMC3046139.
• Kossoff EB, Ngamphaiboon N, Laudico TJ, O'Connor TL. Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients. Med Oncol. 2011 Dec.28 Suppl 1:S115-S120. Pubmedid: 20978949.
• Waldrop DP, O'Connor TL, Trabold N. “Waiting for the other shoe to drop:” distress and coping during and after treatment for breast cancer. J Psychosoc Oncol. 2011 Dec.29(4):450-473. Pubmedid: 21966727.
• Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O'Connor TL. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. Clin Breast Cancer. 2011 Aug.11(4):252-257. Pubmedid: 21729657.
• Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat. 2011 Apr.126(3):797-802. Pubmedid: 21197567.
• Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. NCCN Clinical Practice Guidelines Cancer-related fatigue. J Natl Compr Canc Ne. 2010 Aug.8(8):904-931. Pubmedid: 20870636.
• O'Connor TL, Kossoff E. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer. Pharmacotherapy. 2009 Aug.29(8):993-996. Pubmedid: 19637953.
• O'connor T, Rustum Y, Levine E, Creaven P. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother Pharmacol. 2008 Jan.61(1):125-131. Pubmedid: 17426973.
• Mock V, Abernethy A, Atkinson A, Barsevick A, Berger A, Cella D, CimprichB, Cleeland C, Eisenberger M, Escalante C, Hinds P, Jacobsen P, Kaldor P, O'Connor T, Otis-Green S, Piper B, Pirl W, Rugo H, Sabbatini P, Stewart F, Wagner L. Cancer-related fatigue. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2007 Nov.5(10):1054-1078. Pubmedid: 18053429.
• Bush E, Geradts J, O'Connor T. An unusual cause of cholecystitis?. Am J Clin Oncol. 2005 Oct.28(5):529-530. Pubmedid: 16199997.